These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 25623304)

  • 1. Relationship between circulating tumor cells, blood coagulation, and urokinase-plasminogen-activator system in early breast cancer patients.
    Mego M; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Luha J; Gronesova P; Pindak D; Fridrichova I; Celec P; Reuben JM; Cristofanilli M; Mardiak J
    Breast J; 2015; 21(2):155-60. PubMed ID: 25623304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship Between Circulating Tumor Cells and Tissue Plasminogen Activator in Patients with Early Breast Cancer.
    Bystricky B; Jurisova S; Karaba M; Minarik G; Benca J; Sedlácková T; Tothova L; Vlkova B; Cierna Z; Janega P; Manasova D; Gronesova P; Pindak D; Mardiak J; Celec P; Mego M
    Anticancer Res; 2017 Apr; 37(4):1787-1791. PubMed ID: 28373442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour cells are linked to plasma D-dimer levels in patients with metastatic breast cancer.
    Mego M; Zuo Z; Gao H; Cohen EN; Giordano A; Tin S; Anfossi S; Jackson S; Woodward W; Ueno NT; Valero V; Alvarez RH; Hortobagyi GN; Khoury JD; Cristofanilli M; Reuben JM
    Thromb Haemost; 2015 Mar; 113(3):593-8. PubMed ID: 25373787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
    Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship Between Circulating Tumor Cells and Annexin A2 in Early Breast Cancer Patients.
    Bystricky B; Cierna Z; Sieberova G; Janega P; Karaba M; Minarik G; Benca J; Sedlackova T; Jurisova S; Gronesova P; Pindak D; Macuch J; Mardiak J; Mego M
    Anticancer Res; 2017 May; 37(5):2727-2734. PubMed ID: 28476852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer.
    Banys-Paluchowski M; Witzel I; Aktas B; Fasching PA; Hartkopf A; Janni W; Kasimir-Bauer S; Pantel K; Schön G; Rack B; Riethdorf S; Solomayer EF; Fehm T; Müller V
    Sci Rep; 2019 Feb; 9(1):2318. PubMed ID: 30783124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
    Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
    BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCR4-SDF-1 interaction potentially mediates trafficking of circulating tumor cells in primary breast cancer.
    Mego M; Cholujova D; Minarik G; Sedlackova T; Gronesova P; Karaba M; Benca J; Cingelova S; Cierna Z; Manasova D; Pindak D; Sufliarsky J; Cristofanilli M; Reuben JM; Mardiak J
    BMC Cancer; 2016 Feb; 16():127. PubMed ID: 26896000
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
    Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
    Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression and clinical significance of coagulate and fibrolysis factors in tissue and plasma from hepatocellular carcinoma patients].
    Zhou Q; Liang LJ; Peng BG; Zhen YY
    Ai Zheng; 2006 Nov; 25(11):1433-8. PubMed ID: 17094916
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Circulating Tumor Cells With Epithelial-to-mesenchymal Transition Phenotypes Associated With Inferior Outcomes in Primary Breast Cancer.
    Mego M; Karaba M; Minarik G; Benca J; Silvia J; Sedlackova T; Manasova D; Kalavska K; Pindak D; Cristofanilli M; Reuben JM; Mardiak J
    Anticancer Res; 2019 Apr; 39(4):1829-1837. PubMed ID: 30952723
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
    Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
    Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Measurement of plasminogen activator system components in plasma and tumor tissue extracts obtained from patients with breast cancer: an EORTC Receptor and Biomarker Group collaboration.
    Grebenchtchikov N; Maguire TM; Riisbro R; Geurts-Moespot A; O'Donovan N; Schmitt M; McGreal G; McDermott E; O'Higgins N; Brünner N; Sweep CG; Duffy MJ
    Oncol Rep; 2005 Jul; 14(1):235-9. PubMed ID: 15944795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circulating tumour cells are associated with increased risk of venous thromboembolism in metastatic breast cancer patients.
    Mego M; De Giorgi U; Broglio K; Dawood S; Valero V; Andreopoulou E; Handy B; Reuben JM; Cristofanilli M
    Br J Cancer; 2009 Dec; 101(11):1813-6. PubMed ID: 19888227
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy.
    Mego M; Mani SA; Lee BN; Li C; Evans KW; Cohen EN; Gao H; Jackson SA; Giordano A; Hortobagyi GN; Cristofanilli M; Lucci A; Reuben JM
    Int J Cancer; 2012 Feb; 130(4):808-16. PubMed ID: 21387303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complexes between urokinase-type plasminogen activator and its receptor in blood as determined by enzyme-linked immunosorbent assay.
    De Witte H; Sweep F; Brünner N; Heuvel J; Beex L; Grebenschikov N; Benraad T
    Int J Cancer; 1998 Jul; 77(2):236-42. PubMed ID: 9650559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implications of the co-detection of the urokinase plasminogen activator system and osteopontin in patients with non-small-cell lung cancer undergoing radiotherapy and correlation with gross tumor volume.
    Ostheimer C; Evers C; Bache M; Reese T; Vordermark D
    Strahlenther Onkol; 2018 Jun; 194(6):539-551. PubMed ID: 29340706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumour cells and hypercoagulability: a lethal relationship in metastatic breast cancer.
    Kirwan CC; Descamps T; Castle J
    Clin Transl Oncol; 2020 Jun; 22(6):870-877. PubMed ID: 31473984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex of urokinase-type plasminogen activator with its type 1 inhibitor predicts poor outcome in 576 patients with lymph node-negative breast carcinoma.
    Manders P; Tjan-Heijnen VC; Span PN; Grebenchtchikov N; Geurts-Moespot A; van Tienoven DT; Beex LV; Sweep FC
    Cancer; 2004 Aug; 101(3):486-94. PubMed ID: 15274061
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients.
    Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q
    Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.